Complement Therapeutics gains €72m in Series A financing for novel therapeutics research
April 17, 2023Medical Communications
Preclinical stage biotechnology company Complement Therapeutics (CTx) has announced the completion of its Series A financing round, led by Gimv, …
GSK announces positive data from phase 3 trial for new UTI antibiotic
April 17, 2023Research and Development
GSK has shared positive data from its phase 3 trial for gepotidacin as a new oral antibiotic for the treatment …
Merck acquires Prometheus Biosciences, strengthens immunology pipeline
April 17, 2023Sales and Marketing
Merck (known as MSD outside of the US and Canada) has announced that it, through a subsidiary, has agreed to …
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
April 17, 2023Business Services
BOSTON and WILMINGTON, Del. – April 16, 2023 – MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: …
MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
April 17, 2023Business Services
Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group …
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
April 14, 2023Business Services
NEW YORK, April 14, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical …
Neuromod closes €30m financing for new tinnitus treatment device
April 14, 2023Sales and Marketing
Irish medical device company Neuromod has announced that it has successfully closed a €30m financing intended to further commercialise Lenire, …
Diabeloop announces collaboration with Novo Nordisk for connected diabetes treatment
April 14, 2023Research and Development
Automated insulin delivery company Diabeloop has announced its collaboration with global healthcare company Novo Nordisk, with an agreement which covers …
Merck’s relapsing multiple sclerosis trial put on FDA partial clinical hold over liver injuries
April 14, 2023Research and Development
Merck has announced that its clinical phase 3 study EVOLUTION has been put on partial clinical hold by the FDA …
FDA declines Eli Lilly’s bowel disease drug over manufacturing issues
April 14, 2023Manufacturing and Production
Pharma giant Eli Lilly’s Biologic Licence Application (BLA) for its bowel disease drug has been declined by the FDA over …
UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal
April 13, 2023Business Services
Brussels (Belgium) 13 April 2023 – 07:00 AM (CET) – UCB, a global biopharmaceutical company, today announced that The Lancet Neurology …
Adaptyv Bio creates a new paradigm for protein engineering using generative AI, open-source software and synthetic biology
April 13, 2023Business Services
Lausanne, Switzerland – 13th April 2023; AI tools like ChatGPT are revolutionizing how the world generates text, images and code. …
BioInnovation Institute & Science Prize for Innovation winners announced
April 13, 2023Business Services
COPENHAGEN, Denmark, April 13, 2023 – BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, …
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 13, 2023Sales and Marketing
Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …
ANGLE plc (“the Company”) Pharma Services Contract with Crescendo Biologics
April 13, 2023Business Services
ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has signed a …
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
April 13, 2023Business Services
Strasbourg, France, April 12, 2023, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops …
Alentis Therapeutics closes $105m Series C funding for new treatment options
April 13, 2023Sales and Marketing
Alentis Therapeutics has announced $105m in Series C funding which was led by Jeito Capital together with Novo Holdings A/S …
Biogen announces licensing of Denali’s ATV to target Amyloid Beta
April 13, 2023Research and Development
Biogen and Denali Therapeutics have announced that Biogen has exercised its option to license Denali’s Antibody Transport Vehicle: Amyloid beta …
Aspect Biosystems and Novo Nordisk partner with $75m deal to develop bioprinted tissue therapeutics
April 13, 2023Research and Development
Canadian biotech company Aspect Biosystems and Denmark-based Novo Nordisk have announced a collaboration, development and license agreement to develop bioprinted …
Kala Pharmaceuticals receives FDA Fast Track Designation for human MSC-S therapy
April 13, 2023Medical Communications
Clinical-stage biopharmaceutical company Kala Pharmaceuticals has announced that the FDA has granted it Fast Track Designation for its human mesenchymal …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
